Xoft to Launch Axxent(R) Xpress(TM) Transportable Electronic Brachytherapy Vehicles at ASTRO Meeting

Thursday, September 18, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

BOSTON, Sept. 18 Xoft, Inc., developer of the Axxent(R)Electronic Brachytherapy System (eBx), which delivers non-radioactive,X-ray-based radiation treatment directly to cancer sites with minimal exposureto surrounding healthy tissue, announced that it will launch the AxxentXpress(TM) Mobile Electronic Brachytherapy Vehicles to expand and improveaccess to critical radiation therapy. The announcement was made in advance ofthe 49th American Society for Therapeutic Radiology and Oncology (ASTRO)Meeting, September 21-24.

Xoft also announced that it has collaborated with Medical Coaches Inc., aleading manufacturer of custom mobile medical and specialty vehicles, todesign and manufacture the specialized medical vehicles, as well as completethe extensive Department of Transportation (DOT) certification process. Xoftand Medical Coaches will showcase an Axxent Xpress Mobile ElectronicBrachytherapy Van in a dedicated booth at the ASTRO Meeting.

"Eliminating the need to deliver treatment in heavily shielded vaults,Electronic Brachytherapy was designed to help radiation oncologists improveaccess to critical cancer care and make it available to patients acrossgeography and socioeconomic levels," said Michael Klein, president and CEO ofXoft. "Adding the ability to provide mobile radiation therapy services is anatural progression; one we hope will further improve access for the tens ofthousands of breast cancer patients who do not comply with their prescribedradiation treatment or otherwise would not receive it. Studies presented atthe recent ASCO Breast Cancer Symposium support prior findings that much ofthis problem is based on inability to access therapy because of distance,fear, or difficulty with the logistics of getting to traditional radiationcenters -- issues that are addressed with electronic brachytherapy."

Commercially available for accelerated treatment of early stage breastcancer and endometrial and rectal indications, the Axxent ElectronicBrachytherapy System is also cleared for use in the treatment of other cancersor conditions where radiation therapy is indicated. Designed to deliverelectronic, X-ray-based radiation treatment, the proprietary Axxent treatmentplatform can be used in many clinical settings under the supervision of aradiation oncologist, without the need for a shielded room. As a platformtechnology, the Axxent System addresses a variety of oncological andnon-oncological indications and is designed to deliver non-radioactive therapydirectly to cancer sites with minimal radiation exposure to surroundinghealthy tissue.

In its treatment of early stage breast cancer, the Axxent ElectronicBrachytherapy System provides the opportunity to reduce the therapy timerequired from seven weeks (for external radiation therapy) down to five days.As a result, tens of thousands of patients will have greater access to therapythat is delivered more easily and conveniently. This may accelerate patientchoice of breast sparing lumpectomy surgery with adjuvant radiation therapyover the alternative of a full mastectomy.

"Medical Coaches has worked with some of the largest medical companies fordecades bringing critical diagnostic and therapeutic equipment to wherepatients need it most," said Geoff Smith, president of Medical Coaches. "Weare very proud to be working with Xoft on the Axxent Xpress vehicles to helpimprove access to radiation therapy in outlying and underserved areas."

The new Axxent Xpress Mobile van has been custom designed by experts fromboth Xoft and Medical Coaches. The van will be able to carry up to threeAxxent System HDR controllers. The controllers will ride on an easy to drivesprinter van modified to provide the safest transport environment.Modifications include ride softening shock absorbers and rear heating andcooling to insure equipment is ready to operate at delivery. A speciallybuilt easy to u

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store